



6901 Rockledge Drive, Suite #700
Bethesda, Maryland 20817

For Immediate Release
29-August-2007

Contact: Noelle Todd
+(1) 301.214.7631

Cardiocore Acquires Experienced Cardiac Safety Team Formerly with Gentiae *Fastest Growing Cardiac Core Lab Adds Polina Voloshko, MD and Team of Industry Veterans*

29-August-2007, Washington, DC – Cardiocore, a premier centralized cardiac safety testing laboratory, announced today that it has hired former Gentiae Vice President of Cardiovascular Clinical Services, Polina Voloshko, MD. Cardiocore also acquired key members of Dr. Voloshko's former staff. This core group includes cardiovascular physicians and technicians as well as project and data managers. Members of the team have worked together for 20 years, originally as part of the esteemed Ischemia Research and Education Foundation.

Dr. Voloshko joins Cardiocore's scientific consulting team which includes two of the core lab industry's founding fathers— Chief Medical Officer Lawrence Z. Satin, MD, FACC and Senior Cardiac Safety Consultant, Daniel B. Goodman, MD. With this addition, Cardiocore continues to expand its international scientific leadership, keeping pace with the company's growing base of pharmaceutical and biotech clients.

Dr. Satin noted, "Cardiocore's scientific team has overseen roughly a third of all the Thorough QT studies that have been performed to date. By bringing together the thought leadership from three top core labs, we have established a scientific foundation that is uniquely broad. We've combined the 'best of the best' approaches from across the industry to provide sponsors with unparalleled value."

"When leading scientists like Polina Voloshko and Daniel Goodman become available in the cardiac testing industry," added Cardiocore CEO Jennifer Cotteleer, "they are in a position to join any core lab they choose. Therefore, I am proud to see the most prominent experts repeatedly attracted to Cardiocore. They recognize us as the new industry leader, and they're attracted to the scientific integrity we've established."

"As a recent competitor," explained Dr. Voloshko, "I can tell you that Cardiocore is setting the standard to which other core labs aspire. This organization delivers the highest quality science and the most thoughtful customer care in the cardiac testing industry. Speaking for myself and my colleagues, we are all delighted to become contributors to this top-quality operation."

Dr. Voloshko brings 22 years of international experience as a cardiologist and researcher. In her role as Vice President of Medical Operations, she will perform protocol consulting, provide medical leadership and direct the company's echocardiography services. She will be located in Cardiocore's San Francisco, California office enabling close collaboration with West Coast life sciences customers.

About Cardiocore

Cardiocore has provided superior centralized cardiac testing services to the pharmaceutical industry for 14 years. Services include centralized electrocardiographic (ECG) analysis, Holter monitoring, echocardiography, statistical analysis and consulting services such as protocol design. The company is experienced in design and implementation of Thorough QT Trials and cardiac safety and efficacy testing in Phase I, II and III clinical trials. These services are supported by the company's CardioCorrect[®] system featuring the proprietary HolterGateway[™] and CardioPortal[™]. Cardiocore's U.S. headquarters is located in Bethesda, Maryland, its West Coast office is located in San Francisco, California, and its European subsidiary, Cardiocore Limited, is located in London, England.